Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXO-CD24 for Moderate or Severe COVID-19
NCT04969172Phase 2Unknown
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of exosomes overexpressing CD24 in coronavirus disease 2019 (COVID-19). Status: unknown.
02
Drugs
exosomes overexpressing CD24
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04969172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969172.